Iatrogenic comorbidity in childhood and adolescence: New insights from the use of antidepressant drugs

CNS Drugs

Volumn 28, Issue 9, 2014, Pages 769-774

  Offidani, Emanuela ^a   Fava, Giovanni A ^b,c   Sonino, Nicoletta ^c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ANXIETY DISORDERS; CASE REPORT; CHILD; COMORBIDITY; FEMALE; HUMAN; IATROGENIC DISEASE; MALE; MOOD DISORDERS; RISK;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CHILD; COMORBIDITY; FEMALE; HUMANS; IATROGENIC DISEASE; MALE; MOOD DISORDERS; RISK;

EID: 84929130906     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0184-0     Document Type: Article

References (31)

1. Brent RL, Tanski S, Weitzman M. A pediatric perspective on the unique vulnerability and resilience of the embryo and the child to environmental toxicants. Pediatrics. 2004;113(4 Suppl):935-44.
2. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry. 2011;72(5):655-70.
3. Safer DJ. Age-grouped differences in adverse drug events from psychotropic medication. J Child Adolesc Psychopharmacol. 2011;21:299-309.
4. Bylund DB, Reed AL. Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs? Neurochem Int. 2007;51(5):246-53.
5. Greenhill LL, Vitiello B, Riddle MA, Fisher P, Shockey E, March JS, Levine J, Fried J, Abikoff H, Zito JM, McCracken JT, Findling RL, Robinson J, Cooper TB, Davies M, Varipatis E, Labellarte MJ, Scahill L, Walkup JT, Capasso L, Rosengarten J. Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2003;42(6):627-33.
6. Di Mascio A, Shader RI. Behavioral toxicity of psychotropic drugs: I. Definition. II. Toxic effect on psychomotor function. Conn Med. 1968;32:617-20.
7. Di Mascio A, Shader RI. Behavioral toxicity of psychotropic drugs: III. Effect on perceptual and cognitive functions. IV. Effect on emotional (mood) states. Conn Med. 1968;32:771-5.
8. Di Mascio A, Shader RI. Behavioral toxicity of psychotropic drugs: V effects on gross behavioral patterns. Conn Med. 1968;33:279-81.
9. Perl M, Hall RCW, Gardner ER. Behavioral toxicity of psychiatric drugs. In: Hall RCW, editor. Psychiatric presentations of medical illness. New York: Spectrum Publications; 1980. p. 311-36.
10. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry. 1987;48:13-9.
11. Zito MJ, Safer DJ, Craig TJ. Pharmacoepidemiology of psychiatric disorders. In: Hartzema AG, Tilson HH, Chan KA, editors. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Whitney Books; 2008. p. 817-54.
12. Fava GA, Tomba E, Tossani E. Innovative trends in the design of clinical trials in psychopharmacology and psychotherapy. Progr Neuropsychopharmacol Biol Psychiatry. 2013;40:306-11.
13. Fava GA, Tossani E, Bech P, Berrocal C, Chouinard G, Csillag C, Wittchen HU, Rief W. Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research. Int J Methods Psychiatr Res. 2014;23(Sl):92-101.
14. Fava GA, Offidani E. The mechanisms of tolerance in antidepressant action. Progr Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1593-602.
15. Barlow DH. Negative effects from psychological treatments. Am Psychol. 2010;65(1):13-20.
16. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chron Dis. 1970;23:455-68.
17. Leckman JF. The risks and benefits of antidepressants to treat pediatric-onset depression and anxiety disorders: a developmental perspective. Psychother Psychosom. 2013;82(3):129-31.
18. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-96.
19. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363(9418):1341-5.
20. Offidani E, Fava GA, Tomba E, Baldessarini RJ. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom. 2013;82(3):132-41.
21. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004;158(8):773-80.
22. Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, Hetrick SE. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD008324. doi: 10.1002/14651858.CD008324.
23. Richardson WS, Doster LM. Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness and vulnerability. J Clin Epidemiol. 2014;67:244-6.
24. Fava GA. Modern psychiatric treatment. Psychother Psychosom. 2013;82:1-7.
25. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355-62.
26. Balon R. Benzodiazepines revisited. Psychother Psychosom. 2013;82(6):353-4.
27. Rickels K. Should benzodiazepines be replaced by antidepressants in the treatment of anxiety disorders? Fact or fiction? Psychother Psychosom. 2013;82(6):351-2.
28. Cosci F, Fava GA. Staging of mental disorders: systematic review. Psychother Psychosom. 2013;82(1):20-34.
29. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429-36.
30. Hall RCW, Stickney SK, Gardner ER. Behavioral toxicity of nonpsychiatric drugs. In: Hall RCW, editor. Psychiatric presentations of medical illness. New York: Spectrum Publications; 1980. p. 337-406.
31. Fava GA, Sonino N. Depression associated with medical illness: treatment considerations. CNS Drugs. 1996;5:175-89.